Vincent Van Ginneken,Verheij E, De Vries E and Van der Greef J
Erasmus MC, Netherlands
TNO Pharma, Netherlands
Sino-Dutch Center for Preventive and Personalized Medicine, Netherlands
Scientific Tracks Abstracts: J Cancer Sci Ther
This lipidomics study was designed to find via a high-fat (HF) diet induced insulin resistant (IR) and/or type-2 diabetes (T2DM) C57Bl/6 mouse model potential novel biomarkers. Major aiming was to find following this lipidomics based approach novel safe biomarkers applicable for humans with IR/T2DM that can be used in the assessment of diagnosis, intensive treatment, clinical use and new drug development. In addition, the biomarker has to be found in blood-plasma simultaneously while it is not a component of the HF-diet. Reversed phase liquid chromatography coupled to mass spectrometry (LCMS) were used to quantify and qualify the rearrangement and repartitioning of fat stores in the heart, hind limb, carcass muscle, liver, brain and blood plasma of this mice model following a systems biology lipidomics based approach. Two potential biomarkers were found for this HF-diet mouse model. The first biomarker was a 20:3 cholesteryl-ester (20:3-ChE) which significantly increased (Pâ?¤0.016) in the fatty heart with 1317% while it rose very significantly (Pâ?¤0.00001) in blood plasma with 1013% in the HF diet group in comparison to the control-group (Co). The second biomarker was a 36:1 phosphatidylcholine (36:1-PC), which rose significantly (Pâ?¤0.025) mainly in heart muscle with 400% while concentrations increased significantly strongly (Pâ?¤0.002) in blood plasma with 1493% in the high-fat diet vs. Co. As an earlier defined prerequisite, both compounds were not found in the food. The 20:3-ChE biomarker (dihomo-Î³-linolenic; 20:3 n-6) has been classified as a potential type 2 diabetes biomarker (T2DM) in a human cohort of the Uppsala Longitudinal Study of Adult Men (ULSAM). In addition, we give a biochemical explanation for the 36:1-PC as hypoxic biomarker for cardiovascular diseases (CVD) diagnosis and therapy. Both biomarkers are interesting candidates for further validation in human cohorts.
Vincent Van Ginneken has completed his first PhD from Leiden University in Mathematics and Natural Sciences followed by Post-doctoral studies resulting in a second PhD at Wageningen University and Research in Agricultural Sciences. He is the Scientific Director of Blue-Green Technologies, a think-tank organization with several disciplines: biomedical, agricultural and seaweed biotechnology. He has published more than 115 papers in reputed journals like Nature and has been serving as an Editorial Board Member of some of these reputed journals. Presently, he is involved as Researcher on lipidomics based cancer/tumor research following a systems biology approach in Erasmus Medical Centre Rotterdam, Netherlands.
E-mail: [email protected]
Cancer Science & Therapy received 3358 citations as per Google Scholar report